Dr Friederike Schlurmann (Centre Hospitalier Universitaire de Brest, Brest, France), Prof Boris Hadaschik (University of Duisburg-Essen, Essen, Germany), and Prof Karim Fizazi (Institut Gustave Roussy, Villejuif, France) discuss the real-world evidence regarding PSA in prostate cancer.

The panel talks about the real-world prostate-specific antigen (PSA) response and disease progression among patients with non-metastatic castration-resistant prostate cancer and metastatic prostate cancer.

They elaborate on the value of PSA in decision-making and trial design. The panel also discusses the PSA test and the variables associated with false-positive PSA results.